logo
logo

Ensem Therapeutics, A Cbc Group-Incubated Biopharma Company, Raises $67 Million In Series A Financing To Develop Small Molecule Medicines For Difficult-To-Drug Targets

Ensem Therapeutics, A Cbc Group-Incubated Biopharma Company, Raises $67 Million In Series A Financing To Develop Small Molecule Medicines For Difficult-To-Drug Targets

04/06/22, 4:00 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgboston
Money raised
$67 million
Industry
science and engineering
data and analytics
health care
software
Round Type
series a
ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, Inc., and CBC Group, bringing the series A total to $67 million.

Company Info

Company
Ensem Therapeutics
Location
boston, massachusetts, united states
Additional Info
ENSEM is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas. ENSEM integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on high-value and difficult-to-drug targets. For more information, please visit www.ensemtx.com.